Last reviewed · How we verify
Placebo to Alendronate
Alendronate works by inhibiting osteoclast-mediated bone resorption.
Alendronate works by inhibiting osteoclast-mediated bone resorption. Used for Treatment of osteoporosis in postmenopausal women and men, Treatment of glucocorticoid-induced osteoporosis.
At a glance
| Generic name | Placebo to Alendronate |
|---|---|
| Sponsor | Amgen |
| Drug class | Bisphosphonate |
| Target | Hydroxyapatite |
| Modality | Small molecule |
| Therapeutic area | Osteoporosis |
| Phase | Phase 3 |
Mechanism of action
Alendronate is a bisphosphonate that binds to hydroxyapatite in bone, inhibiting osteoclast-mediated bone resorption and leading to an increase in bone mineral density. This results in a decrease in the risk of fractures and other bone-related complications.
Approved indications
- Treatment of osteoporosis in postmenopausal women and men
- Treatment of glucocorticoid-induced osteoporosis
Common side effects
- Abdominal pain
- Dyspepsia
- Back pain
- Arthralgia
- Headache
Key clinical trials
- Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes (PHASE2)
- Prospective, Randomized, Multicenter Clinical Trial of Bisphosphonates Combined With Vancomycin for the Treatment of Cierny-Mader Type I and III Osteomyelitis (PHASE3)
- Bone, Exercise, Alendronate, and Caloric Restriction (PHASE4)
- Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis (PHASE3)
- A Randomized Control Trial Phase (IIIa) Unicentric, Placebo Controlled, Double-Blinded Efficacy and Safety of Topical Alendronic Acid on Alveolar Bone Remodeling After Tooth Extraction (PHASE3)
- A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED) (PHASE3)
- A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211) (PHASE3)
- A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to Alendronate CI brief — competitive landscape report
- Placebo to Alendronate updates RSS · CI watch RSS
- Amgen portfolio CI